Fig. 1: Investigator-assessed PFS. | Nature Communications

Fig. 1: Investigator-assessed PFS.

From: Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort

Fig. 1

Reported for A, the Chinese cohort overall population and B, patients with PIK3CA/AKT1/PTEN-altered tumors. The hazard ratio of the capivasertib–fulvestrant (purple) and placebo–fulvestrant (blue) curves was estimated with the use of the Cox proportional hazards model, with stratification according to the presence or absence of liver metastases and previous use of a CDK4/6 inhibitor (yes or no) in the overall population, and according to previous CDK4/6 inhibitor use in the population of patients with PIK3CA/AKT1/PTEN-altered tumors. Tick marks indicate censored data. AKT1 Akt serine/threonine kinase 1, CDK4/6 cyclin-dependent kinase 4/6, CI confidence interval, PIK3CA catalytic subunit alpha of phosphatidylinositol-3-kinase, PFS progression-free survival, PTEN phosphatase and tensin homolog.

Back to article page